Opening Question Why do some people have life-changing experiences with psychedelic therapy while others struggle with difficult or even harmful outcomes? The answer often lies in three crucial factors that researchers call "set," "setting," and safety protocols—elements that can make the difference between therapeutic breakthrough...
Opening Question Is microdosing psychedelics the breakthrough wellness trend that supporters claim, or are we getting ahead of the science? As millions of people around the world experiment with tiny doses of LSD and psilocybin mushrooms, researchers are racing to understand whether these practices actually...
Opening Question Could psilocybin therapy offer hope for people with bipolar 2 depression who have been excluded from most psychedelic research due to safety concerns? A groundbreaking new study suggests that psilocybin-assisted therapy might be both safe and effective for this underserved population, potentially opening...
Opening Question Could a nasal spray be the breakthrough that millions of people with treatment-resistant depression have been waiting for? The FDA's recent approval of Spravato (esketamine) as a standalone treatment marks a historic moment in mental health care—but what do the clinical trial results...